Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina-Reference-Cited by-同舟云学术

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

Published:2021-04-15 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Wurcel Victoria^ORCID,Chirovsky Diana,Borse Rebekah,Altuna Juan Ignacio,Carabajal Fernando,Gandhi Jyotika

Funder

Merck & Co

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01656-3.pdf

Reference48 articles.

1. Head and Neck Cancers-National Cancer Institute. 2020. https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet Accessed 30 Oct 2020.

2. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans—Painting, Firefighting, and Shiftwork [Internet]. Vol. 98. Lyon, France; 2010. Available from: https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono98.pdf. Accessed 29 Oct 2020.

3. Union for International Cancer Control Public Health. Locally advanced squamous carcinoma of the head and neck-Executive Summary. https://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf. 2014. https://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf. Accessed 24 Nov 2020.

4. International Agency for Research on Cancer—Globocan 2018. Global cancer statistics [Internet]. 2018 [cited 2020 Nov 24]. Available from: https://gco.iarc.fr/today. Accessed 24 Nov 2020.

5. National Cancer Institute—Surveillance, Epidemiology and ERP. Laryngeal Cancer—Cancer Stat Facts [Internet]. Available from: https://seer.cancer.gov/statfacts/html/laryn.html. Accessed 30 Oct 2020.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment;PharmacoEconomics;2023-01-19

2. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States;Journal of Medical Economics;2022-07-23

3. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis;Oral Oncology;2022-06

4. Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis;Frontiers in Pharmacology;2022-05-20

5. Pembrolizumab cost effective as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma;PharmacoEconomics & Outcomes News;2021-05